Compare DexCom, Inc. (DXCM) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs KLA Corp. — how do they compare? DexCom, Inc. trades at $85.15 (market cap $31.86B), while KLA Corp. trades at $201.16 (market cap $256.72B). The key difference: KLA Corp. is far larger — about 8.1× DexCom, Inc.'s market cap, and KLA Corp. pays a 0.47% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and KLA Corp. for 60 Days on average.
| DXCM | KLAC | |
|---|---|---|
Market Cap | $31.86B | $256.72B |
Volume | 3,607,070 | 9,970,753 |
Sector | Health | Technology |
52-Week High | $92.34 | $301.71 |
52-Week Low | $54.84 | $98.28 |
Typical Hold Time | 62 Days | 60 Days |
Enterprise Value | $31.32B | $257.97B |
Dividend Yield | — | 0.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal despite strong fundamentals. The company reported Q2 2026 EPS of $0.70, beating estimates, continuing a trend of earnings outperformance. Revenue growth is robust, with 2025 revenue reaching $4.66 billion and net income margin improving to 20.12%. Analyst consensus is strongly bullish with an 80.77% buy rating and a $95.07 price target, suggesting significant upside from current levels.
The outlook for DXCM is positive driven by expansion in continuous glucose monitoring for Type 2 diabetes, as highlighted in recent company reports. Key risks include competitive pressures and reimbursement challenges. With solid cash flow generation and institutional support, the stock presents a growth opportunity, though investors should monitor execution against high expectations.
KLA Corporation (KLAC) trades at $196.83, down 0.32% on the day, with strong technical support at $194 and resistance at $198. The company demonstrates robust fundamentals with revenue growth from $9.8B in 2024 to $12.16B in 2025 and net income margin expanding to 35.57%. Recent earnings have consistently beaten expectations, with Q2 2026 EPS of $1.05 surpassing the $1.00 estimate. AI-driven demand is fueling backlog growth to $12.57B, positioning KLAC for continued expansion in semiconductor equipment markets.
KLAC presents a compelling growth opportunity with strong analyst support (28 buys vs 2 sells) and a $223.88 consensus price target offering 14% upside. However, elevated valuation ratios (P/E 53.75, P/S 19.12) and competitive pressures from Applied Materials and ASML represent key risks. The stock's technical bullish signal and institutional accumulation support near-term momentum, though margin compression and semiconductor cycle volatility warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
